Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17133094 | SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR | December 2020 | November 2022 | Abandon | 22 | 1 | 1 | No | No |
| 17133460 | CONFECTIONS FOR SKIN PROTECTION: COMPOSITIONS, METHODS FOR MAKING, AND APPLICATIONS THEREOF | December 2020 | May 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17254900 | ORAL COMPOSITIONS AND MUCOADHESIVE THIN FILMS FORMED THEREFROM | December 2020 | June 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17127589 | ANTIVIRAL COMPOSITIONS AND METHODS OF USING SAME | December 2020 | September 2022 | Allow | 21 | 1 | 1 | No | No |
| 17252961 | FORMULATIONS OF 5-HYDROXY TRYPTOPHAN (5-HTP) FOR BETTER BIOAVAILABILITY FOR VARIOUS INDICATIONS | December 2020 | July 2023 | Abandon | 31 | 2 | 1 | No | No |
| 17251605 | COMPOSITIONS AND METHODS FOR IN SITU-FORMING TISSUE CONSTRUCTS | December 2020 | March 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17112591 | CALLUS LYSATE COMPRISING HIGH CONTENT OF CALLUS METABOLITE AND PREPARATION METHOD THEREOF | December 2020 | January 2024 | Allow | 38 | 4 | 1 | Yes | No |
| 17110249 | Composition and method for treating and healing Medication-Related Osteonecrosis of the Jaw (MRONJ) | December 2020 | May 2023 | Abandon | 29 | 1 | 0 | Yes | No |
| 17059534 | TOPICAL COMPOSITION | November 2020 | September 2023 | Allow | 33 | 3 | 1 | Yes | No |
| 16499726 | NON-AQUEOUS COMPOSITION HAVING DRUG CARRIED THEREIN, AND METHOD FOR PRODUCING SAME | November 2020 | July 2022 | Abandon | 34 | 1 | 0 | No | No |
| 17101590 | METHOD FOR BONE TISSUE REGENERATION IN EXPERIMENTS | November 2020 | April 2022 | Allow | 17 | 1 | 0 | Yes | No |
| 17057142 | PEPTIDES ENCAPSULATED IN LECITHIN AND ALGINATE | November 2020 | September 2023 | Abandon | 34 | 2 | 1 | No | No |
| 17098038 | METHOD OF ENHANCING HAIR GROWTH | November 2020 | May 2022 | Abandon | 18 | 1 | 0 | No | No |
| 17096856 | ORAL COMPOSITIONS FOR POST-DENTAL IMPLANTS | November 2020 | June 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 17053605 | PHARMACEUTICAL COMPOSITION COMPRISING SMALL MOLECULE EGFR INHIBITOR AND PREPARATION METHOD THEREFOR | November 2020 | August 2022 | Abandon | 21 | 1 | 1 | No | No |
| 17086702 | PROTECTING ORAL OVERDOSE WITH ABUSE DETERRENT IMMEDIATE RELEASE FORMULATIONS | November 2020 | May 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17085166 | COSMETIC COMPOSITIONS | October 2020 | November 2024 | Abandon | 49 | 2 | 0 | No | No |
| 17051909 | PROCESS FOR PREPARING POLYSUCCINIMIDE DERIVATIVES-BASED MICROCAPSULES | October 2020 | March 2023 | Allow | 29 | 3 | 1 | No | No |
| 17049468 | ULTRASOUND-INDUCED DRUG DELIVERY SYSTEM USING DRUG CARRIER COMPRISING NANOBUBBLES AND DRUG | October 2020 | August 2023 | Allow | 34 | 3 | 1 | No | No |
| 17075447 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AND METHODS OF USING THE SAME | October 2020 | July 2022 | Allow | 21 | 1 | 1 | No | No |
| 17073068 | CHEWABLE GEL FORMULATIONS | October 2020 | November 2022 | Abandon | 25 | 2 | 0 | No | No |
| 17068297 | COMPOSITION AND DRESSING WITH NITRIC OXIDE | October 2020 | May 2022 | Abandon | 19 | 1 | 0 | No | No |
| 15733741 | NANOPARTICLE COMPOSITIONS AND METHODS OF USE OF PARP INHIBITOR FOR TREATMENT OF CANCER | October 2020 | January 2025 | Abandon | 51 | 4 | 1 | No | No |
| 17045691 | SPHERICAL MICROPARTICLES | October 2020 | November 2023 | Abandon | 37 | 3 | 1 | Yes | No |
| 17063325 | SANITISING COMPOSITION | October 2020 | November 2022 | Abandon | 25 | 2 | 0 | No | No |
| 16962414 | PHARMACEUTICAL COMPOSITION, PATCH AND MANUFACTURING METHOD THEREOF, ANALGESIC METHOD, AND APPLICATION | October 2020 | May 2023 | Abandon | 34 | 2 | 1 | No | No |
| 17044598 | ORAL GUM FORMULATION AND FABRICATION PROCESS THEREOF | October 2020 | February 2024 | Abandon | 41 | 4 | 1 | No | No |
| 17043923 | A NOVEL SYNERGIC HERBAL FORMULATION FOR THE PREVENTION AND TREATMENT OF PRE-DIABETES, DIABETES AND OTHER INSULIN RESISTANCE CASES | September 2020 | September 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16982741 | NICOTINE GEL | September 2020 | April 2025 | Abandon | 55 | 6 | 1 | Yes | No |
| 16979937 | PROCESS FOR PREPARING MICROCAPSULES WITH IMPROVED DEPOSITION | September 2020 | June 2023 | Allow | 34 | 4 | 1 | Yes | No |
| 17016542 | METHODS FOR THE TREATMENT OF ROSACEA | September 2020 | May 2023 | Abandon | 33 | 6 | 0 | Yes | No |
| 17014276 | STABLE NIMODIPINE PARENTERAL FORMULATION | September 2020 | August 2022 | Abandon | 24 | 2 | 0 | No | No |
| 17011345 | STABLE NIMODIPINE PARENTERAL FORMULATION | September 2020 | May 2022 | Allow | 20 | 2 | 0 | Yes | No |
| 17003760 | PLANT ACTIVES AND THEIR ANTI-POLLUTION EFFECTS THEREOF | August 2020 | April 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16975042 | PROCESS FOR PREPARING MICROCAPSULES | August 2020 | December 2023 | Abandon | 39 | 5 | 1 | Yes | No |
| 16971758 | Improvements in or Relating to Organic Compounds | August 2020 | December 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16971355 | GRANULAR COMPOSITION, PRODUCTION METHOD FOR GRANULAR COMPOSITION, AND DISSOLUTION PROPERTY IMPROVEMENT METHOD FOR GRANULAR COMPOSITION | August 2020 | May 2024 | Abandon | 45 | 4 | 0 | No | No |
| 16994847 | Compositions, Methods and Uses for Cleaning, Disinfecting and/or Sterilizing | August 2020 | January 2024 | Allow | 41 | 5 | 0 | No | No |
| 16994862 | Compositions, Methods and Uses for Cleaning, Disinfecting and/or Sterilizing | August 2020 | March 2024 | Allow | 43 | 5 | 0 | Yes | No |
| 16968284 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | August 2020 | March 2022 | Allow | 20 | 1 | 0 | No | No |
| 16985585 | POLYUREA CAPSULES PREPARED WITH ALIPHATICISOCYANATES AND AMINES | August 2020 | December 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16966221 | O/W EMULSION COMPRISING PHOTOCHEMICALLY STABLE 4-(TERT-BUTYL)-4-METHOXYDIBENZOYLMETHANE IN OIL DROPLETS SMALLER THAN 8 MICROMETERS | July 2020 | April 2023 | Abandon | 33 | 2 | 1 | No | Yes |
| 16958375 | METHODS OF CANCER TREATMENT USING AN ATR INHIBITOR | June 2020 | November 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16954968 | OXADIAZOLE DERIVATIVES AS RHO-KINASE INHIBITORS | June 2020 | October 2022 | Allow | 28 | 1 | 0 | No | No |
| 16897863 | COMPOSITIONS FOR INSECT REPELLANT | June 2020 | December 2021 | Abandon | 19 | 3 | 0 | Yes | No |
| 16770656 | NON-SPHERICAL MICROCAPSULE | June 2020 | June 2024 | Abandon | 48 | 6 | 1 | No | No |
| 16770847 | PEPTIDE COMPOSITIONS FOR SLOWING DEGRADATION OF VITAMIN MINERAL SUPPLEMENTS, FOODS, PHARMACEUTICAL AND COSMETICS | June 2020 | November 2023 | Allow | 41 | 3 | 1 | Yes | No |
| 15931604 | SEMI-SOLID CHEWABLE GEL CANNABINOID COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | May 2020 | December 2022 | Abandon | 31 | 2 | 0 | No | No |
| 16872204 | USE OF ZINC AND COPPER GLUCONATE IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | May 2020 | December 2023 | Abandon | 43 | 5 | 0 | No | No |
| 16850748 | PLATINUM(IV) CONJUGATES AND METHODS OF USE | April 2020 | May 2022 | Allow | 25 | 1 | 1 | No | No |
| 16844135 | LIGNIN BIOMATERIAL AS AGRICULTURAL DRUG CARRIER | April 2020 | January 2022 | Allow | 21 | 2 | 0 | No | No |
| 16820177 | METHOD OF MANUFACTURING PHARMACEUTICAL COMPOSITIONS | March 2020 | November 2021 | Allow | 20 | 3 | 0 | Yes | No |
| 16820190 | PHARMACEUTICAL COMPOSITION, COMPRISING PHOSPHATE BINDER PARTICLES | March 2020 | November 2021 | Allow | 20 | 3 | 0 | Yes | No |
| 16818275 | PARENTERAL ADMINISTRATION OF TAPENTADOL | March 2020 | May 2023 | Abandon | 39 | 4 | 1 | No | No |
| 16816845 | SUNSCREEN COMPOSITIONS WITH IMPROVED WATER RESISTANCE OF UVA SUNSCREEN ACTIVE AGENTS | March 2020 | May 2023 | Abandon | 38 | 4 | 1 | No | No |
| 16640756 | METHOD FOR PREPARING AT LEAST PARTIALLY DRIED GRANULES | February 2020 | May 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16790950 | COMPOSITIONS AND METHODS FOR INDUCTION OF REMISSION OF INFLAMMATORY BOWEL DISEASES | February 2020 | December 2021 | Abandon | 22 | 2 | 0 | No | No |
| 16782888 | COMPOSITION FOR THE TREATMENT OF SUPERFICIAL LESIONS | February 2020 | February 2022 | Abandon | 24 | 2 | 1 | No | No |
| 16781797 | Sustained Release Pharmaceutical Compositions and Methods of Use | February 2020 | June 2021 | Abandon | 16 | 1 | 1 | No | No |
| 16636063 | HEMOPEXIN FORMULATIONS | February 2020 | April 2025 | Allow | 60 | 6 | 1 | Yes | Yes |
| 16780158 | POLYUREA CAPSULE COMPOSITIONS | February 2020 | December 2024 | Allow | 58 | 9 | 0 | No | No |
| 16634163 | TRANEXAMIC ACID SPRAY FOR KNEE ARTHROPLASTY | January 2020 | January 2021 | Allow | 12 | 1 | 0 | No | No |
| 16752590 | PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING PYRIDOSTIGMINE AND AN NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVIS | January 2020 | April 2023 | Allow | 39 | 2 | 1 | No | No |
| 16734413 | Synthetic Nicotine Composition | January 2020 | May 2021 | Allow | 16 | 1 | 0 | No | No |
| 16628463 | NOVEL PHARMACEUTICAL COMPOSITION | January 2020 | July 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16720909 | AGENT TO BE APPLIED TO OPHTHALMIC DEVICE | December 2019 | April 2022 | Abandon | 28 | 3 | 0 | Yes | No |
| 16621463 | SEVELAMER FOR THE TREATMENT AND/OR PREVENTION OF AORTIC STENOSIS | December 2019 | February 2021 | Abandon | 14 | 1 | 0 | No | No |
| 16705287 | Serum Cholesterol Lowering Edible Product | December 2019 | December 2022 | Abandon | 36 | 4 | 1 | No | No |
| 16704829 | TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGS | December 2019 | September 2021 | Abandon | 22 | 2 | 0 | No | No |
| 16616209 | NICOTINE-CONTAINING CHEWING GUM COMPOSITIONS | November 2019 | February 2023 | Abandon | 39 | 4 | 1 | No | No |
| 16682862 | REDUCED PERMEABILITY MICROCAPSULES | November 2019 | July 2023 | Allow | 44 | 2 | 1 | No | No |
| 16678980 | COMBINATION THERAPY COMPRISING NANOPARTICLES OF A TAXANE AND ALBUMIN WITH ABT-263 IN METHODS FOR TREATING CANCER | November 2019 | December 2020 | Abandon | 13 | 1 | 0 | No | No |
| 16662917 | SKIN LIGHTENING COMPOSITIONS | October 2019 | August 2021 | Abandon | 22 | 3 | 0 | No | No |
| 16592033 | POLYUREA OR POLYURETHANE CAPSULES | October 2019 | May 2025 | Allow | 60 | 6 | 0 | No | Yes |
| 16498746 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENTS | September 2019 | September 2022 | Allow | 36 | 3 | 1 | No | No |
| 16498284 | SOLVENT-FREE METHOD OF ENCAPSULATING A HYDROPHOBIC ACTIVE | September 2019 | May 2022 | Allow | 32 | 3 | 0 | Yes | No |
| 16564467 | METHOD OF ENHANCING HAIR GROWTH | September 2019 | November 2020 | Abandon | 14 | 1 | 0 | No | No |
| 16491683 | WOUND HEALING MEDICAMENT | September 2019 | April 2024 | Abandon | 55 | 4 | 1 | Yes | No |
| 16560370 | CHROMATOGRAPHIC MEDIA FOR STORAGE AND DELIVERY OF THERAPEUTIC BIOLOGICS AND SMALL MOLECULES | September 2019 | September 2024 | Abandon | 60 | 5 | 0 | No | Yes |
| 16540707 | Compositions, Methods and Uses for Cleaning, Disinfecting and/or Sterilizing | August 2019 | April 2020 | Allow | 8 | 0 | 0 | Yes | No |
| 16540733 | Compositions, Methods and Uses for Cleaning, Disinfecting and/or Sterilizing | August 2019 | April 2020 | Allow | 8 | 0 | 0 | Yes | No |
| 16534980 | SEMI-SOLID TOPICAL COMPOSITION CONTAINING PIRFENIDONE AND MODIFIED DIALLYL DISULFIDE OXIDE (M-DDO) FOR ELIMINATING OR PREVENTING ACNE | August 2019 | January 2021 | Allow | 18 | 2 | 0 | No | No |
| 16511752 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING RETINAL NEURODEGENERATION | July 2019 | November 2019 | Allow | 4 | 1 | 0 | Yes | No |
| 16447198 | COMPOSITIONS AND METHODS OF USE FOR TREATMENT OF MAMMALIAN DISEASES | June 2019 | November 2020 | Abandon | 17 | 1 | 0 | No | No |
| 16442512 | COMPOSITIONS AND METHODS FOR INTRACELLULAR IRON DISPLACEMENT PROTEINS | June 2019 | January 2022 | Abandon | 31 | 4 | 1 | No | Yes |
| 16469268 | Orally Disintegrated Tablet Comprising Carbamate Compound | June 2019 | May 2025 | Allow | 60 | 4 | 1 | No | Yes |
| 16466073 | ANTIMICROBIAL SHAPE MEMORY POLYMERS | June 2019 | April 2021 | Allow | 22 | 2 | 1 | Yes | No |
| 16397322 | Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids | April 2019 | August 2020 | Allow | 16 | 1 | 1 | Yes | No |
| 16394430 | NANOBUBBLES IN AN ABSORBENT MATERIAL | April 2019 | April 2022 | Abandon | 36 | 4 | 0 | Yes | No |
| 16344708 | POLYURETHANE-HYDROGEL COMPOSITION COMPRISING CHLORHEXIDINE | April 2019 | July 2022 | Abandon | 39 | 3 | 1 | Yes | No |
| 16393378 | ARTICLES AND METHODS OF TREATING VASCULAR CONDITIONS | April 2019 | September 2024 | Abandon | 60 | 7 | 0 | Yes | No |
| 16343473 | NOVEL COMPOSITIONS ACTIVE ON ADIPOCYTES | April 2019 | July 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16388222 | CANNABIS PLACEBO COMPOSITIONS, DELIVERY VEHICLES AND A METHOD FOR COLOUR MATCHING/NEUTRALIZATION OF CANNABIS PRODUCTS | April 2019 | March 2021 | Abandon | 23 | 0 | 1 | No | No |
| 16342523 | CLEAVABLE SURFACTANT | April 2019 | February 2022 | Allow | 34 | 3 | 1 | Yes | No |
| 16382921 | Sustained Release Pharmaceutical Dosage Form of Entecavir | April 2019 | April 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16377039 | TOPICAL COMPOSITIONS AND METHODS OF MANUFACTURING THEM IN SPECIFICALLY TREATED STEEL VESSELS | April 2019 | April 2022 | Abandon | 36 | 3 | 0 | No | No |
| 16338894 | JANUS PARTICLES AND THEIR USE FOR SURFACTANT-FREE CLEANSING AND EMULSION STABILIZATION | April 2019 | July 2024 | Abandon | 60 | 3 | 1 | Yes | No |
| 16371393 | MICROCAPSULE COMPOSITIONS WITH IMPROVED DEPOSITION | April 2019 | October 2020 | Abandon | 18 | 0 | 1 | No | No |
| 16369844 | TREATMENT OF ENTERIC STRESS FROM HEAT AND INFECTION IN HUMANS AND ANIMALS BY SUPPLEMENTATION WITH ZINC AND BUTYRIC ACID | March 2019 | July 2022 | Abandon | 40 | 4 | 0 | Yes | No |
| 16336588 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | March 2019 | October 2020 | Abandon | 18 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PHAN, DOAN THI-THUC.
With a 25.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PHAN, DOAN THI-THUC works in Art Unit 1613 and has examined 552 patent applications in our dataset. With an allowance rate of 43.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner PHAN, DOAN THI-THUC's allowance rate of 43.1% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PHAN, DOAN THI-THUC receive 2.79 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PHAN, DOAN THI-THUC is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +57.9% benefit to allowance rate for applications examined by PHAN, DOAN THI-THUC. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 13.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.9% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 26.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 55.7% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 32.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 70.3% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.